GLP-1s Cancer Survival: Diabetes Study Reveals Advantage
Table of Contents
Managing type 2 diabetes (T2D) alongside a cancer diagnosis presents a complex health challenge. Both conditions, and their treatments, can significantly impact a patient’s well-being, making it difficult to maintain optimal nutrition and energy levels. However, emerging research suggests that certain diabetes medications, specifically GLP-1 receptor agonists (GLP-1 RAs), may offer a survival advantage for older adults with T2D and cancer.
The Interplay of Cancer Treatment, Diabetes, and Nutrition
Cancer treatments, such as chemotherapy, can induce side effects like nausea and fatigue. These symptoms directly interfere with a patient’s ability to consume adequate nutrition, leading to unintended weight loss and further weakening. Additionally, medications commonly prescribed to manage chemotherapy-induced nausea, such as steroids, can inadvertently elevate blood sugar levels, complicating diabetes management.Despite these hurdles, maintaining stable blood sugar control is paramount during cancer treatment. Effective diabetes management can reduce the risk of infections,which are particularly dangerous for immunocompromised cancer patients,and can positively influence overall treatment outcomes. The Centers for Disease Control and Prevention (CDC) advises individuals with diabetes and cancer to focus on a balanced meal plan, prioritizing nutrient-dense foods that are higher in calories and protein when feeling well enough. Incorporating appetite-stimulating and enjoyable foods is also recommended to support nutritional intake.
GLP-1 Receptor Agonists: A Closer Look in Diabetes and Cancer
Recent research has begun to explore the potential impact of GLP-1 RAs on survival rates in individuals managing both T2D and cancer. A retrospective cohort study utilizing Medicare data from 2013 to 2020 investigated the association between GLP-1 RA use and all-cause mortality in older adults (aged 66 and above) diagnosed with T2D and one of nine specific cancers: thyroid, pancreatic, bladder, colorectal, lung, kidney, breast, endometrial, or prostate.
The study involved two primary comparisons: GLP-1 RAs versus SGLT2 inhibitors, and GLP-1 RAs versus dipeptidyl peptidase-4 (DPP4) inhibitors. In the GLP-1 RA versus SGLT2 inhibitor comparison, 2553 matched pairs were analyzed with a median follow-up of 1.65 years. The GLP-1 RA versus DPP4 inhibitor comparison included 2564 matched pairs with a median follow-up of 1.7 years.
The findings indicated that among older patients with T2D and cancer, the use of GLP-1 RAs was associated with a lower risk of all-cause mortality when compared to DPP4 inhibitor use. Importantly, no notable difference in mortality was observed when GLP-1 ras were compared to SGLT2 inhibitors. This survival benefit over DPP4 inhibitors remained consistent across various demographic groups, including age, sex, non-Hispanic White individuals, obesity status, and specific cancer types such as colorectal, lung, and breast cancer. While previous studies have suggested that the effect of GLP-1 expression on cancer survival can vary by cancer type, this research provides valuable new evidence on the comparative effectiveness of GLP-1 RAs in this complex patient population.
Future Directions and Considerations
It is crucial to acknowledge the limitations of this retrospective study, including potential confounding factors and the need for further investigation in certain subgroup analyses. the authors emphasize the necessity of prospective clinical trials to definitively confirm the role of GLP-1 RAs in improving cancer survivorship. Still, these findings offer a promising avenue for discussion and further research into optimizing treatment strategies for individuals living with both diabetes and cancer.
REFERENCES
- Radwan RM, Lu Y, Dai H, et al. GLP-1 RA Use and survival Among Older Adults With Cancer and Type 2 Diabetes. JAMA Netw Open. 2025; 8 (7): E2521887. DOI: 10.1001/JamanetWorkOPen.2025.21887
- CDC. I Have Diabetes and Cancer. What Can I Eat? News release. May 15, 2024. Accessed July 25,2025. https://www.cdc.gov/diabetes/healthy-eating/diabetes-and-cancer-what-to-eat.html